---
title: treatment of hodgkin lymphoma (HL)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[hodgkin lymphoma (HL)]]

# treatment of hodgkin lymphoma (HL) #ğŸš§ æ–½å·¥ä¸­

## treatment of hodgkin lymphoma (HL)
(NCCN Guidelines v5.2021)
* [[Stages Iâ€“II Hodgkin lymphoma]]
* [[Stages IIIâ€“IV Hodgkin lymphoma]]
* [[Refractory_relapsed Hodgkin lymphoma]] : salvage chemo + auto HSCT Â± RT

## [[brentuximab vedotin]] (BV) 3ï¸âƒ£ 0ï¸âƒ£
* Anti-CD30 antibodyâ€“drug conjugate therapy in lymphoma
* ä¸”IPS (International Prognostic Score)ç‚º4-7 åˆ†çš„CD30+
* ç¬¬IVæœŸä½•å‚‘é‡‘æ°æ·‹å·´ç˜¤(HL)æˆäººç—…äºº
* post-ASCT yields some long-term remissions (Blood 2016;128:1562)

## PD1/PDL1 blockade (pembrolizumab or nivolumab) (NEJM 2015;372:311, JCO 2017;35:19)

## Late treatment effects include â†‘ risk for:
* Second cancers: ~4.6Ã— risk for up to 40 y (NEJM 2015;373:2499)
* breast (if RT), âˆ´ annual screening at age 40 or 8â€“10 y post RT; leukemia/MDS; NHL
* Cardiac disease (if RT or [[anthracycline]]), ? role of echo/stress at 10 y (controversial)
* pulmonary toxicity (if [[bleomycin]]); Hypothyroidism (if RT), âˆ´ annual TSH (if neck RT)
* International Prognostic Score (IPS; JCO 2012;30:3383) risk factors: albumin <4 g/dL, Hb <10.5 g/dL, male gender, age >45 y, stage IV, WBC â‰¥15 k/ÂµL, lymphocytes <600/ÂµL or <8% of diff. 5-yr PFS 62â€“88% based on # of risk factors.

